SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Hadda waxaa lagu baarayaa marxaladda 2aad ee tijaabada muhiimka ah, CART-ddBCMA waa daawaynta unugyada T-unuga ee Arcellx iyadoo la adeegsanayo isku-xidhka cusub ee shirkadda, D-Domain. Kite iyo Arcellx waxay si wada jir ah u horumarin doonaan oo ay ganacsi u samayn doonaan hantida CART-ddBCMA ee gudaha Maraykanka
Daaweynta T-Cell-ka Baabuurka Waxay ka mid tahay daawaynta horumarsan ee noocyada kansarka dhiigga qaarkood. Waxa socda in ka badan 750 tijaabada caafimaadka in CAR T-Cell daaweynta Shiinaha hadda. Bukaanka raba in ay isdiiwaangeliyaan way la soo xidhiidhi karaan Faa'iidada Kansarka Khadka caawinta bukaanka ee WhatsApp + 91 96 1588 1588 ama emayl ku soo dir info@cancerfax.com.
Ku saabsan Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory Meelo badan (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, initiated in the fourth quarter of 2022.
Ku saabsan Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Ku saabsan sayniska Gilead
Gilead Sciences, Inc. waa shirkad biopharmaceutical ah oo daba galisay oo ku guulaysatay horumarka daawada in ka badan sodon sano, iyada oo ujeedadu ahayd in loo abuuro adduun ka caafimaad badan dadka oo dhan. Shirkadda waxaa ka go'an in ay horumariso dawooyinka hal-abuurka leh si looga hortago loona daweeyo cudurrada nafta halis gelinaya, oo ay ku jiraan HIV, cagaarshowga fayraska iyo kansarka. Gilecaad waxay ka shaqeysaa in ka badan 35 waddan oo adduunka ah, oo xarunteedu tahay Foster City, California. Sayniska Gilecaad waxay heshay Kite 2017.
